New Potomac Partners LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 6.2% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,524 shares of the company’s stock after selling 100 shares during the quarter. New Potomac Partners LLC’s holdings in Johnson & Johnson were worth $252,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently modified their holdings of JNJ. Moneta Group Investment Advisors LLC raised its position in shares of Johnson & Johnson by 90,144.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the period. Norges Bank bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $4,609,399,000. Providence Capital Advisors LLC increased its holdings in Johnson & Johnson by 141,974.0% during the 1st quarter. Providence Capital Advisors LLC now owns 4,750,956 shares of the company’s stock worth $30,651,000 after acquiring an additional 4,747,612 shares during the period. Morgan Stanley increased its holdings in Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after acquiring an additional 4,521,062 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in Johnson & Johnson by 15.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after acquiring an additional 3,849,148 shares during the period. Institutional investors own 68.40% of the company’s stock.
Johnson & Johnson Trading Up 0.6 %
Shares of JNJ opened at $158.53 on Tuesday. The stock has a market capitalization of $412.01 billion, a P/E ratio of 32.09, a PEG ratio of 3.19 and a beta of 0.55. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. The firm has a fifty day simple moving average of $164.12 and a two-hundred day simple moving average of $162.46. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $181.04.
Johnson & Johnson Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were given a $1.19 dividend. The ex-dividend date of this dividend was Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 3.00%. Johnson & Johnson’s dividend payout ratio is 96.36%.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on JNJ shares. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Friday, September 29th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Monday. Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Credit Suisse Group increased their price target on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Finally, Morgan Stanley decreased their price target on shares of Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating on the stock in a report on Thursday, August 31st. Nine equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $171.06.
View Our Latest Stock Report on Johnson & Johnson
Insider Transactions at Johnson & Johnson
In other news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- MarketBeat ‘Stock of the Week’ Ford, Strike Presents Opportunity
- CD Calculator: Certificate of Deposit Calculator
- Healthcare Giant Outperforms: A Healthy Dose of Market Resilience
- How to Invest in Grocery Stores
- 5 Reasons Rivian is a Buy on Shaken Investor Sentiment
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
